Your browser doesn't support javascript.
loading
Reduction of Neutrophil Activation by Phosphodiesterase 4 Blockade in Behçet's Disease.
Le Joncour, Alexandre; Régnier, Paul; Maciejewski-Duval, Anna; Charles, Erwan; Barete, Stéphane; Fouret, Pierre; Rosenzwajg, Michelle; Klatzmann, David; Cacoub, Patrice; Saadoun, David.
  • Le Joncour A; Sorbonne Université, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), Laboratoire d'excellence TRANSIMMUNOM, Paris, and Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, Paris, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, P
  • Régnier P; Sorbonne Université, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), Paris, and Laboratoire d'excellence TRANSIMMUNOM, Paris, and Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, Paris, France.
  • Maciejewski-Duval A; Sorbonne Université, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), Paris, and Laboratoire d'excellence TRANSIMMUNOM, Paris, and Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, Paris, France.
  • Charles E; Sorbonne Université, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), Paris, and Laboratoire d'excellence TRANSIMMUNOM, Paris, and Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, Paris, France.
  • Barete S; Sorbonne Université, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), Paris, and Laboratoire d'excellence TRANSIMMUNOM, Paris, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Paris, and AP-HP, Groupe Hospitalier Pitié-Salpêtr
  • Fouret P; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Anatomopathology, Paris, France.
  • Rosenzwajg M; Sorbonne Université, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), Paris, and Laboratoire d'excellence TRANSIMMUNOM, Paris, and Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, Paris, France.
  • Klatzmann D; Sorbonne Université, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), Paris, and Laboratoire d'excellence TRANSIMMUNOM, Paris, and Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, Paris, France.
  • Cacoub P; Sorbonne Université, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), Laboratoire d'excellence TRANSIMMUNOM, Paris, and Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, Paris, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, P
  • Saadoun D; Sorbonne Université, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), Laboratoire d'excellence TRANSIMMUNOM, Paris, and Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, Paris, and AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, P
Arthritis Rheumatol ; 75(9): 1628-1637, 2023 09.
Article en En | MEDLINE | ID: mdl-36862398
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndrome de Behçet Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndrome de Behçet Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article